Martel et al. Infections and cancer: established associations and new hypotheses. Crit Rev Oncol Hematol. 2009 Jun;70(3):183-94. doi: 10.1016/j.critrevonc.2008.07.021. Epub 2008 Sep 20. http://www.ncbi.nlm.nih.gov/pubmed/18805702
Fitzgerald et al. Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. J Med Genet. 2010 Jul;47(7):436-44. doi: 10.1136/jmg.2009.074237. http://www.ncbi.nlm.nih.gov/pubmed/20591882
Ciaravalli et al. Histotype-based prognostic classification of gastric cancer. World J Gastroenterol. 2012 Mar 7;18(9):896-904. doi: 10.3748/wjg.v18.i9.896. http://www.ncbi.nlm.nih.gov/pubmed/22408348
Omae et al. Safety, efficacy, and long-term outcomes for endoscopic submucosal dissection of early esophagogastric junction cancer. Gastric Cancer. 2013 Apr;16(2):147-54. doi: 10.1007/s10120-012-0162-5. Epub 2012 Jun 13. http://www.ncbi.nlm.nih.gov/pubmed/22692465
Moehler et al. German S3-guideline „Diagnosis and treatment of esophagogastric cancer“. Z Gastroenterol. 2011 Apr;49(4):461-531. doi: 10.1055/s-0031-1273201. Epub 2011 Apr 7. http://www.ncbi.nlm.nih.gov/pubmed/21476183
Cunningham et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006 Jul 6;355(1):11-20. http://www.ncbi.nlm.nih.gov/pubmed/16822992
Okines et al. Trastuzumab: a novel standard option for patients with HER-2-positive advanced gastric or gastro-oesophageal junction cancer. Therap Adv Gastroenterol. 2012 Sep;5(5):301-18. doi: 10.1177/1756283X12450246. http://www.ncbi.nlm.nih.gov/pubmed/22973416
